Potential role of tigecycline in the treatment of community-acquired bacterial pneumonia

References

• HeronMHoyertDLMurphySLXuJKochanekKDTejada-VeraBDeaths: final data for 2006Natl Vital Stat Rep20095714113419788058
   PubMedGoogle Scholar
• ColiceGLMorleyMAAscheCBirnbaumHGTreatment costs of community-acquired pneumonia in an employed populationChest200412562140214515189934
   PubMed Web of Science ®Google Scholar
• NiedermanMSMandellLAAnzuetoAAmerican Thoracic SocietyGuidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and preventionAm J Respir Crit Care Med200116371730175411401897
   PubMed Web of Science ®Google Scholar
• MandellLAWunderinkRGAnzuetoAInfectious Diseases Society of America; American Thoracic SocietyInfectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adultsClin Infect Dis200744Suppl 2S27S7217278083
   PubMed Web of Science ®Google Scholar
• BTS Pneumonia Guidelines CommitteeBritish Thoracic Society guidelines for the management of community-acquired pneumonia in adults-2004 Update Available from: http://www.britthoracic.org.uk/Portals/0/Clinical%20Information/Pneumonia/Guidelines/MACAPrevisedApr04.pdf. Accessed December 8, 2010.
   Google Scholar
• WoodheadMBlasiFEwigSEuropean Respiratory SocietyEuropean Society of Clinical Microbiology and Infectious DiseasesGuidelines for the management of adult lower respiratory tract infectionsEur Respir J20052661138118016319346
   PubMed Web of Science ®Google Scholar
• FelminghamDComparative antimicrobial susceptibility of respiratory tract pathogensChemotherapy200450Suppl 131015319548
   PubMed Web of Science ®Google Scholar
• JohnsonDMStilwellMGFritscheTRJonesRNEmergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999–2003)Diagn Microbiol Infect Dis2006561697416546341
   PubMed Web of Science ®Google Scholar
• GordonKABiedenbachDJJonesRNComparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance ProgramDiagn Microbiol Infect Dis200346428528912944021
   PubMed Web of Science ®Google Scholar
• TownsendMLPoundMWDrewRHTigecycline: a new glycylcycline antimicrobialInt J Clin Pract200660121662167217109673
   PubMed Web of Science ®Google Scholar
• Wyeth PharmaceuticalsTygacil (Package Insert)Philadelphia (PA)Wyeth Pharmaceuticals2010
   Google Scholar
• BreedtJTerasJGardovskisJTigecycline 305 cSSSI Study GroupSafety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonamAntimicrob Agents Chemother200549114658466616251309
   PubMed Web of Science ®Google Scholar
• SacchidanandSPennRLEmbilJMEfficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trialInt J Infect Dis20059525126116099700
   PubMed Web of Science ®Google Scholar
• BabinchakTEllis-GrosseEDartoisNRoseGMLohETigecycline 301 Study GroupTigecycline 306 Study GroupThe efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial dataClin Infect Dis200541Suppl 5S354S36716080073
   PubMed Web of Science ®Google Scholar
• BergalloCJasovichATegliaO308 Study GroupSafety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacinDiagn Microbiol Infect Dis2009631526118990531
   PubMed Web of Science ®Google Scholar
• TanaseanuCMilutinovicSCalistruPI313 Study GroupEfficacy and safety of tigecycline versus levofloxacin for community-acquired pneumoniaBMC Pulm Med200994419740418
   PubMedGoogle Scholar
• TanaseanuCBergalloCTegliaO308 Study Group313 Study GroupIntegrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumoniaDiagn Microbiol Infect Dis200861332933818508226
   PubMed Web of Science ®Google Scholar
• ChopraIRobertsMTetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistanceMicrobiol Mol Biol Rev200165223226011381101
   PubMed Web of Science ®Google Scholar
• ChopraIHawkeyPMHintonMTetracyclines, molecular and clinical aspectsJ Antimicrob Chemother19922932452771592696
   PubMed Web of Science ®Google Scholar
• SpeerBSShoemakerNBSalyersAABacterial resistance to tetracycline: mechanisms, transfer, and clinical significanceClin Microbiol Rev1992543873991423217
   PubMed Web of Science ®Google Scholar
• BergeronJAmmiratiMDanleyDGlycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protectionAntimicrob Agents Chemother1996409222622288878615
   PubMed Web of Science ®Google Scholar
• RasmussenBAGluzmanYTallyFPInhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclinesAntimicrob Agents Chemother1994387165816607526784
   PubMed Web of Science ®Google Scholar
• TallyFTEllestadGATestaRTGlycylcyclines: a new generation of tetracyclinesJ Antimicrob Chemother19953544494527628979
   PubMed Web of Science ®Google Scholar
• ProjanSJPreclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agentPharmacotherapy2000209 Pt 2219S223S11001329
   PubMed Web of Science ®Google Scholar
• ZhanelGGHomenuikKNicholKThe glycylcyclines: a comparative review with the tetracyclinesDrugs2004641638814723559
   PubMed Web of Science ®Google Scholar
• DeanCRVisalliMAProjanSJSumPEBradfordPAEfflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1Antimicrob Agents Chemother200347397297812604529
   PubMed Web of Science ®Google Scholar
• HornseyMEllingtonMJDoumithMScottGLivermoreDMWoodfordNEmergence of AcrAB-mediated tigecycline resistance in a clinical isolate of Enterobacter cloacae during ciprofloxacin treatmentInt J Antimicrob Agents201035547848120189357
   PubMed Web of Science ®Google Scholar
• HornseyMEllingtonMJDoumithMHudsonSLivermoreDMWoodfordNTigecycline resistance in Serratia marcescens associated with up-regulation of the SdeXY-HasF efflux system also active against cipro-floxacin and cefpiromeJ Antimicrob Chemother201065347948220051474
   PubMed Web of Science ®Google Scholar
• WieczorekPSachaPHauschildTZórawskiMKrawczykMTrynisze-wskaEMultidrug resistant Acinetobacter baumannii–the role of AdeABC (RND family) efflux pump in resistance to antibioticsFolia Histochem Cytobiol200846325726719056528
   PubMed Web of Science ®Google Scholar
• RajendranRQuinnRFMurrayCMcCullochEWilliamsCRamageGEfflux pumps may play a role in tigecycline resistance in Burkholderia speciesInt J Antimicrob Agents201036215115420399621
   PubMed Web of Science ®Google Scholar
• HentschkeMWoltersMSobottkaIRohdeHAepfelbacherMramR mutations in clinical isolates of Klebsiella pneumoniae with reduced susceptibility to tigecyclineAntimicrob Agents Chemother20105462720272320350947
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute (CLSI) [formerly National Committee for Clinical Laboratory Standards (NCCLS)]Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically8th ed.Wayne (PA)CLSI2009
   Google Scholar
• Clinical and Laboratory Standards Institute (CLSI) [formerly National Committee for Clinical Laboratory Standards (NCCLS)]Performance Standards for Antimicrobial Susceptibility Testing–19th Informational SupplementWayne (PA)CLSI2009
   Google Scholar
• Clinical and Laboratory Standards Institute (CLSI) [formerly National Committee for Clinical Laboratory Standards (NCCLS)]Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria7th ed.Wayne (PA)CLSI2007
   Google Scholar
• SaderHSJonesRNStilwellMGDowzickyMJFritscheTRTigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continentsDiagn Microbiol Infect Dis200552318118616105562
   PubMed Web of Science ®Google Scholar
• DarabiAHocquetDDowzickyMJAntimicrobial activity against Streptococcus pneumoniae and Haemophilus influenzae collected globally between 2004 and 2008 as part of the Tigecycline Evaluation and Surveillance TrialDiagn Microbiol Infect Dis2010671788620385351
   PubMed Web of Science ®Google Scholar
• GarrisonMWNuemillerJJIn vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococciInt J Antimicrob Agents200729219119617174074
   PubMed Web of Science ®Google Scholar
• YamamotoTNishiyamaATakanoTCommunity-acquired methicillin-resistant Staphylococcus aureus: community transmission, pathogenesis, and drug resistanceJ Infect Chemother201016422525420336341
   PubMed Web of Science ®Google Scholar
• HagemanJCUyekiTMFrancisJSSevere community-acquired pneumonia due to Staphylococcus aureus, 2003–2004 influenza seasonEmerg Infect Dis200612689489916707043
   PubMed Web of Science ®Google Scholar
• NapolitanoLMBrunsvoldMEReddyRCHyzyRCCommunity-acquired methicillin-resistant Staphylococcus aureus pneumonia and ARDS: 1-year follow-upChest200913651407141219892681
   PubMed Web of Science ®Google Scholar
• MendesRESaderHSDeshpandeLJonesRNAntimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centersDiagn Microbiol Infect Dis200860443343618068326
   PubMed Web of Science ®Google Scholar
• SmithKGouldKARamageGGemmellCGHindsJLangSInfluence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureusAntimicrob Agents Chemother201054138038719858261
   PubMed Web of Science ®Google Scholar
• ZhanelGGPalatnickLNicholKALowDEHobanDJCROSS Study GroupAntimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002Antimicrob Agents Chemother20034761875188112760861
   PubMed Web of Science ®Google Scholar
• KoKSSongJHLeeMYAntimicrobial activity of tigecycline against recent isolates of respiratory pathogens from Asian countriesDiagn Microbiol Infect Dis200655433734116631337
   PubMed Web of Science ®Google Scholar
• WaitesKBDuffyLBDowzickyMJAntimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobialAntimicrob Agents Chemother200650103479348417005838
   PubMed Web of Science ®Google Scholar
• DowzickyMJParkCHUpdate on antimicrobial susceptibility rates among Gram-negative and Gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007Clin Ther200830112040205019108792
   PubMed Web of Science ®Google Scholar
• HalsteadDCAbidJDowzickyMJAntimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance TrialJ Infect2007551495717250897
   PubMed Web of Science ®Google Scholar
• BradfordPAWeaver-SandsDTPetersenPJIn vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infectionsClin Infect Dis200541Suppl 5S315S33216080070
   PubMed Web of Science ®Google Scholar
• El-SolhAAPietrantoniCBhatAMicrobiology of severe aspiration pneumonia in institutionalized elderlyAm J Respir Crit Care Med2003167121650165412689848
   PubMed Web of Science ®Google Scholar
• KennyGECartwrightFDSusceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolonesAntimicrob Agents Chemother20014592604260811502536
   PubMed Web of Science ®Google Scholar
• RoblinPMHammerschlagMRIn vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatisInt J Antimicrob Agents2000161616311185415
   PubMed Web of Science ®Google Scholar
• Wyeth PharmaceuticalsResponse Letter for Tigecycline Inquiry Regarding Legionella pneumophilia in vitro Data (Data on File)Philadelphia (PA)Wyeth Pharmaceuticals2010
   Google Scholar
• EdelsteinPHWeissWJEdelsteinMAActivities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumoniaAntimicrob Agents Chemother200347253354012543655
   PubMed Web of Science ®Google Scholar
• MuralidharanGMicalizziMSpethJRaibleDTroySPharmacokinetics of tigecycline after single and multiple doses in healthy subjectsAntimicrob Agents Chemother200549122022915616299
   PubMed Web of Science ®Google Scholar
• RubinoCMForrestABhavnaniSMTigecycline population pharmacokinetics in patients with community-or hospital-acquired pneumoniaAntimicrob Agents Chemother201054125180518620921315
   PubMed Web of Science ®Google Scholar
• DarlingIMCirincioneBBOwenJSNoncompartmental pharmacokinetics of tigecycline in Phase 3 studies of patients with complicated skin and skin-structure and intra-abdominal infections45th Interscience Conference on Antimicrobial Agents and Chemotherapy [meeting abstract]December 16–19, 2005Washington, DC
   Google Scholar
• MacgowanAPTigecycline pharmacokinetic/pharmacodynamic updateJ Antimicrob Chemother200862Suppl 1i11i1618684702
   PubMed Web of Science ®Google Scholar
• TombsNLTissue distribution of GAR-936, a broad spectrum antibiotic in male rats39th Interscience Conference on Antimicrobial Agents and Chemotherapy [meeting abstract]September 14–17, 1999Chicago, IL
   Google Scholar
• RodvoldKAGotfriedMHCwikMKorth-BradleyJMDukartGEllis-GrosseEJTigeycline (TGC) concentration (Cp) in lung tissue, cerebrospinal fluid (CSF), and bile of human subjects45th Interscience Conference on Antimicrobial Agents and Chemotherapy [meeting abstract]December 16–19, 2005Washington, DC
   Google Scholar
• ConteJEJrGoldenJAKellyMGZurlindenESteady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecyclineInt J Antimicrob Agents200525652352915885987
   PubMed Web of Science ®Google Scholar
• GotfriedMHRodvoldKACwikMTroySMDukartGEllis-GrosseEJAn open-label clinical evaluation of tigecycline concentrations in selected tissues and fluidsClin Pharmacol Ther200577Suppl 298
   Web of Science ®Google Scholar
• SunHKOngCTUmerAPharmacokinetic profile of tige-cycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrationsAntimicrob Agents Chemother20054941629163215793157
   PubMed Web of Science ®Google Scholar
• RodvoldKAGotfriedMHCwikMKorth-BradleyJMDukartGEllis-GrosseEJSerum, tissue and body fluid concentrations of tigecycline after a single 100 mg doseJ Antimicrob Chemother20065861221122917012300
   PubMed Web of Science ®Google Scholar
• ScheetzMHReddyPNicolauDPPeritoneal fluid penetration of tigecyclineAnn Pharmacother200640112064206717047138
   PubMed Web of Science ®Google Scholar
• BurkhardtORauchKKaeverVHademJKielsteinJTWelteTTigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpointInt J Antimicrob Agents200934110110219278835
   PubMed Web of Science ®Google Scholar
• BaldwinDRHoneybourneDWiseRPulmonary disposition of antimicrobial agents: in vivo observations and clinical relevanceAntimicrob Agents Chemother1992366117611801416817
   PubMed Web of Science ®Google Scholar
• HoffmannMDeMaioWJordanRAMetabolic disposition (14C) tigecycline in human volunteers following intravenous infusionAmerican Association of Pharmaceutical Scientists (AAPS) Annual Meeting [meeting abstract]November 7–11, 2004Baltimore, MD
   Google Scholar
• RelloJPharmacokinetics, pharmacodynamics, safety and tolerability of tigecyclineJ Chemother200517Suppl 1122216285354
   PubMed Web of Science ®Google Scholar
• MeagherAKAmbrosePGGraselaTHEllis-GrosseEJPharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agentDiagn Microbiol Infect Dis200552316517116105560
   PubMed Web of Science ®Google Scholar
• MuralidharanGFruncilloRJMicalizziMRaibleDGTroySMEffects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjectsAntimicrob Agents Chemother20054941656165915793165
   PubMed Web of Science ®Google Scholar
• TroySMMuralidharanGMicalizziMMojavarianPSalacinskiLRaibleDThe effects of renal disease on the pharmacokinetics of tigecycline (GAR-936)43rd Interscience Conference on Antimicrobial Agents and Chemotherapy [meeting abstract]September 14–17, 2003Chicago, IL
   Google Scholar
• SaundersSBaird-BellaireSJPatatAAPharmacokinetics of tigecycline (TGC) in patients with hepatic impairmentEuropean Association for Clinical Pharmacology and Therapeutics [meeting abstract]June 24–29, 2005Poznan, Poland
   Google Scholar
• Korth-BradleyJMBaird-BellaireSJPatatAAPharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosisJ Clin Pharmacol20115119310120308689
   PubMed Web of Science ®Google Scholar
• MeagherAKPassarellJACirincioneBBExposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infectionsAntimicrob Agents Chemother20075161939194517353238
   PubMed Web of Science ®Google Scholar
• PassarellJAMeagherAKLioliosKExposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infectionsAntimicrob Agents Chemother200852120421017954694
   PubMed Web of Science ®Google Scholar
• RubinoCMBhavnaniSForrestAPharmacokinetic-pharmacodynamic analysis for efficacy of tigecycline in patients with hospital-or community-acquired pneumonia47th Interscience Conference on Antimicrobial Agents and Chemotherapy [meeting abstract]September 17–20, 2007Chicago, IL
   Google Scholar
• FalagasMEKarageorgopoulosDEDimopoulosGClinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecyclineCurr Drug Metab2009101132119149509
   PubMed Web of Science ®Google Scholar
• Van OgtropMLAndesDStamstadTJIn vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various Gram-positive and Gram-negative bacteriaAntimicrob Agents Chemother200044494394910722495
   PubMed Web of Science ®Google Scholar
• HoffmannMDeMaioWJordanRAMetabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjectsDrug Metab Dispos20073591543155317537869
   PubMed Web of Science ®Google Scholar
• AgwuhKNMacGowanAPharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclinesJ Antimicrob Chemother200658225626516816396
   PubMed Web of Science ®Google Scholar
• CunhaBAPharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsisJ Clin Microbiol2009475161319403778
   PubMed Web of Science ®Google Scholar
• CunhaBAOnce-daily tigecycline therapy of multidrug-resistant and non-multidrug-resistant Gram-negative bacteremiasJ Chemother200719223223317434836
   PubMed Web of Science ®Google Scholar
• FreireATMelnykVKimMJ311 Study GroupComparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumoniaDiagn Microbiol Infect Dis201068214015120846586
   PubMed Web of Science ®Google Scholar
• PeresEKhaledYKrijanovskiOIMycobacterium chelonae necrotizing pneumonia after allogeneic hematopoietic stem cell transplant: report of clinical response to treatment with tigecyclineTranspl Infect Dis2009111576318983415
   PubMed Web of Science ®Google Scholar
• BlanquerDde OteroJPadillaETigecycline for treatment of nosocomial-acquired pneumonia possibly caused by multi-drug resistant strains of Stenotrophomonas maltophiliaJ Chemother200820676176319129079
   PubMed Web of Science ®Google Scholar
• DalyMWRiddleDJLedeboerNADunneWMRitchieDJTigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniaePharmacotherapy20072771052105717594211
   PubMed Web of Science ®Google Scholar
• VasilevKReshedkoGOrasanR309 Study GroupA Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniaeJ Antimicrob Chemother200862Suppl 1i29i4018684704
   PubMed Web of Science ®Google Scholar
• HungWYKogelmanLVolpeGIafratiMDavidsonLTigecycline-induced acute pancreatitis: case report and literature reviewInt J Antimicrob Agents200934548648919540093
   PubMed Web of Science ®Google Scholar
• LipshitzJKruhJCheungPCassagnolMTigecycline-induced pancreatitisJ Clin Gastroenterol20094319318769361
   PubMed Web of Science ®Google Scholar
• GilsonMMoachonLJeanneLAcute pancreatitis related to tigecycline: case report and review of the literatureScand J Infect Dis200840868168318979610
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety CommunicationIncreased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections Available from: http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm#ds. Accessed November 11, 2010.
   Google Scholar
• CurcioDTigecycline for severe infections: the gap between the warning and the necessityJ Antimicrob Chemother2010 Epub ahead of print.
   Google Scholar
• ZimmermanJJHarperDMatschkeKSpethJRaibleDJFruncilloRJTigecycline and digoxin co-administered to healthy men44th Inter-science Conference on Antimicrobial Agents and Chemotherapy [meeting abstract]October 30–November 2, 2004Washington, DC
   Google Scholar
• RaibleDZimmermanJJHarperDSpethJPharmacokinetics and pharmacodynamics of tigecycline and warfain coadministered to healthy subjects45th Interscience Conference on Antimicrobial Agents and Chemotherapy [meeting abstract]December 16–19, 2005Washington, DC
   Google Scholar
• GarrisonMWMuttersRDowzickyMJIn vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007Diagn Microbiol Infect Dis200965328829919733459
   PubMed Web of Science ®Google Scholar